DUSS, ILST, TSLA, AAPL, ATRM & Extended Watchlist

Dussault Apparel, Inc.  DUSS

On Tuesday, DUSS released an 8K containing information regarding its pending acquisition of a gold mining property. This adds substance to this very cheaply-priced stock, and with Wednesday’s session seeing a high of .0011 on more than 10X its 3mo. average volume, now is a good time to start monitoring this stock.

The last significant spike on the DUSS chart took it as high as .0015, so a return to those levels from here could facilitate gains in excess of 50% or more. We’d like to see support continue to hold at .0006-.0007 in order for us to remain interested.


International Star, Inc.  ILST

We are introducing a new momentum play in ILST today. Like DUSS, ILST represents a company that has just shifted its business toward the mining sector.  Wednesday, the stock woke from a slumber, and moved from a low of .001 to as much as .0034 on record volume.

The company is currently working toward getting their claim prepared for production. The Van Deemen Mine property consists of five un-patented claims totaling approx. 100 acres, and an additional 18 un-patented lode claims in the surrounding area. As with any junior mining project, the road to production can be a long one, so there’s no sense of urgency here. But at its current price level and at this stage of the story, we thought it would be a good time to put ILST on the radar, and begin following its journey.


Tesla Motors, Inc. TSLA – Options Ideas

Turning our attention to options trading, we are taking a look at TSLA. With the current conditions on the chart appearing favorable for an uptrend, we are looking at 12/21 $120 Call, which last traded at 11.35, and 12/27 $130 calls, last traded at 6.35.

As you can see on the included chart, conditions appear to be gearing up nicely for a possible surge in PPS.


Apple, Inc. AAPL – Options

AAPL is another candidate to provide us with some good options-trading opportunities based on current conditions. AAPL weekly Calls could provide a nice day-trading opportunity today that could yield fast profits. We want to radar the 550, 555 and 560 calls, because all week long, AAPL has been making huge gains and the weekly Calls have made multi-bag gains.

If today’s action can repeat the activity we saw earlier in the week, we could be looking at some sizable gains from these Calls. AAPL $550 calls closed at .80, $555’s closed at .30, and the $560’s were at .12. It’s always safer to play closer to the money with your strike price, so we’re keeping that in mind. If AAPL can’t make its way past $555, the $560’s may not make the same kind of moves that expect from the $550’s and $555’s.


Aetrium, Inc. ATRM

We’ve been talking about ATRM since last Friday, and highlighted it once again on Monday. It would pull back early in the week, and then on Wednesday we got the move we were looking for. From Tuesday’s low of 4.19, the stock would hit a high of 12.40, marking a possible gain of up to 196% for anyone who loaded up on the dip.


Extended Watchlist:
INOL, JCP, DRYS, DSS, FRO, ZOOM, UPIP, GNK, EGLE

OXBT, MCHX, TWTR & Extended Watchlist

Oxygen Biotherapeutics, Inc. OXBT

OXBT followed our expectations to the letter yesterday. We were heralding the stock for its stellar 560% gain, then mentioned that we would be “on alert for any possible pullbacks, because those will often lead to excellent bounce opportunities.” The monstrous run that had begun a few days prior found its apex, giving way to a significant consolidation. After opening at 9.73, OXBT went as high as 11.40, that’s 17% intraday, and from our original alert low of 1.46 (10/29), a tremendous 681%

Upon the anticipated pullback we saw the stock fall to 6.81, bounce, close at 7.70, and this morning pre-market trades have been going off above the 8.00-mark. Moving forward we’d like to see the stock hold support above yesterday’s low, and continue to make higher lows.

This whole thrill ride was catalyzed when OXBT’s partner Phyxius Pharma announced testing results on its heart medication, ‘Levosimendan’, which showed effectiveness in reducing mortality rates among patients undergoing surgical procedures with reduced cardiac function.Tests at the Duke School of Medicine showed it could potentially reduce unwanted outcomes from open heart surgery by as much as 50%. OXBT has a standing agreement to acquire Phyxius, and by extension, the rights to Levosimendan. This is a story we will continue to follow through to its conclusion.


Marchex, Inc. MCHX

MCHX appeared in yesterday’s extended watchlist and made a nice move, trading in a range from 8.17 to 10.00. That represents a 22% gain, and the stock did manage to close out the session maintaining much of that increase at 9.91.


The Twitter IPO – TWTR

As many of you undoubtedly know, on Wednesday, Twitter priced its shares at $26, and will begin trading on the NYSE today under the symbol TWTR. As we did with Facebook, we are using caution early on, as the conditions seem set to create a “perfect storm” of volatility out of the gate. Demand from the outset is expected to be very high, which would create buying pressure and likely cause a significant increase as the first shares begin trading hands. Some experts believe as much as a 30% initial spike could occur, which we believe would lead a sizable number of investors to take those quick profits off of the table right away. That wave of selling pressure could kick up the volatility, causing some major swings in share price.

On the other hand, if demand for the stock has been underestimated, we could be looking at a maiden run that spans multiple sessions. This is why, and the Facebook IPO certainly provided a good lesson to that effect, we are approaching TWTR with a healthy skepticism. No matter how it all plays out, it will be very interesting to watch. You can be sure we will continue to comment as the situation unfolds.


Extended Watchlist:
GSS, JCP, OXGN, LPSN, NURO, GERN, AGEN(Coming off of recent lows)

ATOS, CTIC, APP & Extended Watchlists

Atossa Genetics, Inc.  ATOS

We tacked ATOS onto our extended watchlist yesterday morning, noting that the stock was in the midst of a “Huge gap down” and that we were “watching for a potential bounce”. Indeed that was the case, as the stock touched a low of 2.54 before a reversal carried it as high 3.18, a 25% intraday gain. As usual, when we see big gap-downs, we are looking out for quick-strike opportunities that allow us to make a rapid profit and a timely exit.We have uncovered a few other stocks fitting that profile that we will be monitoring for similar activity today:

Tower Group Intl. Ltd. TWGP

CEL-SCI Corp. CVM

Celgene Corp. CELGZ


Cell Therapeutics, Inc. CTIC
Another play from yesterday’s extended watchlist, CTIC opened at its low of day, and rumbled upward for a 23% move, closing at the high of day on nearly 12X its 3mo. average volume. In doing so, it managed to break a previous swing high at 1.80, a level we’d like to see hold as support moving forward.

We prepared the the following video chart on CTIC:

With the kind of momentum CTIC built up over the course of the day yesterday, this is one play that will be near the top of our watchlists in the near future. The catalyst here seems to be an agreement announced yesterday between the company and the FDA as outlined in the press release below.

SEATTLE, Oct. 7, 2013 /PRNewswire via COMTEX/ — Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the planned pivotal Phase 3 clinical trial, known as the PERSIST-2 trial, evaluating pacritinib compared to best available therapy, including approved JAK2 inhibitors such as ruxolitinib, in patients with myelofibrosis whose platelet counts are <100,000/uL. The SPA is a written agreement between CTI and the FDA regarding the design, endpoints and planned statistical analysis approach of the trial to be used in support of a potential New Drug Application (NDA) submission. The PERSIST-2 trial is the second of two planned Phase 3 clinical trials in patients with myelofibrosis. CTI expects to initiate the PERSIST-2 clinical trial in the fourth quarter of 2013. >>> FULL STORY


American Apparel, Inc. APP

APP is another stock we have tracked for an extended period of time. We have been watching this one to sniff out a bottom for the past few months, and wanted to re-enter it into the conversation today, as that point may be drawing near. A quick peek at the chart below clearly shows just that:


Extended Watchlist:

JCP, AGEN, CBMX, NAVB, TKMR